Opportunity Information: Apply for RFA AI 09 029
Apply for RFA AI 09 029
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (SBIR R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jul 31, 2009 and posted on Jul 31, 2009.
- Applicants must submit their applications by Nov 9, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (SBIR R43/R44)" is a National Institutes of Health (NIH) funding announcement issued by the National Institute of Allergy and Infectious Diseases (NIAID). Its main goal is to push practical, translational research that can move beyond basic discovery and toward real-world products, specifically new therapeutics and diagnostic technologies that address drug resistant bacterial infections and diseases caused by eukaryotic parasites. In plain terms, the program is aimed at helping small businesses turn promising science into tools clinicians and public health systems can actually use, with an emphasis on pathogens where existing drugs are failing or where resistance is a growing threat.
This opportunity is structured under the Small Business Innovation Research (SBIR) program using the R43 and R44 mechanisms. That means it is designed for eligible small business concerns and supports the typical SBIR progression: Phase I for early feasibility and proof-of-concept work, Phase II for more advanced development and validation, and a Fast Track option that allows applicants to apply for Phase I and Phase II in a more streamlined, continuous package when the project is mature enough to justify that approach. The intent of using these mechanisms is to support product-oriented development milestones that help a small company reduce technical risk, generate key data, and advance a candidate therapeutic or diagnostic toward further investment, regulatory planning, clinical evaluation, or commercialization pathways.
NIAID also notes that this SBIR announcement runs in parallel with a separate opportunity of the same scientific scope that uses the R01 research project grant mechanism (RFA AI 09 026). The practical significance of that detail is that the government is trying to stimulate progress from multiple angles: small businesses through SBIR awards, and more traditional academic or research organizations through the R01 mechanism, all aimed at the same overall scientific and public health targets. The use of the word "partnerships" in the title signals an emphasis on collaborative, development-focused work, often involving interactions among small businesses, academic labs, clinical researchers, contract research organizations, or other groups that can contribute specialized expertise needed to move a technology forward.
Funding for this specific SBIR solicitation (Funding Opportunity Number RFA AI 09 029) was projected at about $3,000,000 in total costs for fiscal year 2010, with an expectation of around five awards. The announcement also makes clear that funding levels in future years would depend on annual appropriations, which is standard language indicating that later-year support is subject to the federal budget process. There is no cost sharing or matching requirement, meaning applicants are not required to provide a formal matching contribution as a condition of the award.
Eligibility is limited to small businesses, consistent with SBIR rules. The opportunity is categorized as a discretionary grant in the health domain, and it is associated with CFDA 93.856 (Microbiology and Infectious Diseases Research). Key dates included a posting date of July 31, 2009, and an application closing date of November 9, 2009, with an archive date of December 10, 2009, indicating the solicitation was time-limited and is now archived.
Overall, this FOA is best understood as a targeted NIAID investment meant to accelerate the development pipeline for anti-infective therapeutics and diagnostics in areas where resistance and hard-to-treat pathogens pose major and growing risks. It seeks proposals that are clearly translational, development-driven, and aligned with deliverables that can realistically move a product candidate closer to deployment. For applicants needing the complete official details, the NIH listing provided an additional information link to the full announcement and pointed to NIH Office of Extramural Research contact support for access or technical issues.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (SBIR R43/R44)."
Which agency and institute are offering this funding opportunity?
This is a National Institutes of Health (NIH) funding announcement issued by the National Institute of Allergy and Infectious Diseases (NIAID).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number listed for this SBIR solicitation is RFA AI 09 029.
What is the main purpose of this program?
The goal is to advance practical, translational research that moves beyond basic discovery toward real-world products, specifically new therapeutics and diagnostic technologies for drug resistant bacterial infections and diseases caused by eukaryotic parasites.
What kinds of projects are a good fit for this FOA?
Projects that are development-driven and product-oriented, with clear translational milestones aimed at moving a therapeutic or diagnostic candidate forward (for example, reducing technical risk, generating key data, and advancing toward regulatory planning, clinical evaluation, commercialization pathways, or further investment).
What pathogens or disease areas does this FOA focus on?
The focus is on drug resistant bacteria and eukaryotic parasites, particularly where existing drugs are failing or resistance is a growing threat.
What does "therapeutics and diagnostics" mean in the context of this FOA?
It refers to technologies intended to treat infections (therapeutics) and technologies intended to detect or identify infections (diagnostics), with an emphasis on development that can lead to real-world clinical or public health use.
What funding mechanisms does this opportunity use?
This opportunity uses the SBIR mechanisms R43 and R44.
What is the SBIR program structure described here?
The FOA follows the typical SBIR progression: Phase I for early feasibility and proof-of-concept work, Phase II for more advanced development and validation, and a Fast Track option to apply for Phase I and Phase II in a streamlined package when the project is mature enough.
What is Phase I intended to support?
Phase I is intended for early feasibility and proof-of-concept work.
What is Phase II intended to support?
Phase II is intended for more advanced development and validation of the therapeutic or diagnostic technology.
What is the Fast Track option?
Fast Track allows applicants to apply for Phase I and Phase II together in a more streamlined, continuous package, typically when the project is sufficiently mature to justify that approach.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR rules.
Does the FOA require cost sharing or matching funds?
No. The announcement states there is no cost sharing or matching requirement.
How much funding was projected for this solicitation?
The FOA projected about $3,000,000 in total costs for fiscal year 2010.
How many awards were expected?
The announcement anticipated around five awards.
Is future-year funding guaranteed?
No. The FOA notes that funding levels in future years depend on annual appropriations, meaning support is subject to the federal budget process.
What does "partnerships" imply in this FOA?
The title signals an emphasis on collaborative, development-focused work, often involving interactions among small businesses and partners such as academic labs, clinical researchers, contract research organizations, or other groups that provide specialized expertise needed to move a technology forward.
Is there a related opportunity for non-small business applicants?
Yes. NIAID notes this SBIR announcement runs in parallel with a separate opportunity of the same scientific scope using the R01 research project grant mechanism (RFA AI 09 026), aimed at more traditional academic or research organizations.
What is the practical significance of having a parallel R01 opportunity?
It indicates the government is trying to stimulate progress from multiple angles: SBIR awards to support small businesses and R01 awards to support traditional research organizations, all aligned to the same scientific and public health targets.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.856 (Microbiology and Infectious Diseases Research).
What type of award is this categorized as?
It is categorized as a discretionary grant in the health domain.
When was this FOA posted?
The posting date listed is July 31, 2009.
What was the application closing date?
The application closing date listed is November 9, 2009.
Is this funding opportunity still open?
No. The solicitation was time-limited and is archived. The archive date listed is December 10, 2009.
Where can applicants find the complete official details?
The NIH listing referenced an additional information link to the full announcement and pointed to NIH Office of Extramural Research contact support for access or technical issues.
What is the overall emphasis NIAID is looking for in applications?
The FOA emphasizes translational, development-driven proposals with deliverables that can realistically move a therapeutic or diagnostic product candidate closer to deployment for high-need pathogens affected by drug resistance or difficult-to-treat infections.
Browse more opportunities from the same category: Health
Next opportunity: Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01)
Previous opportunity: Salmon Lake Special Recreation Management Area Trails Invasive Plant Study, Alaska
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 09 029
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 09 029) also looked into and applied for these:
| Funding Opportunity |
|---|
| Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01) Apply for RFA AI 09 026 Funding Number: RFA AI 09 026 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| CHASS Clinical HIV/AIDS Services Strengthening Mozambique Apply for 674 09 062 Funding Number: 674 09 062 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $135,700,000 |
| HLA Region Genomics in Immune Mediated Diseases (U01, U19) Apply for RFA AI 09 030 Funding Number: RFA AI 09 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for High Throughput Structure Determination (U54) Apply for RFA GM 10 005 Funding Number: RFA GM 10 005 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Straight Talk on Preventing HIV Program Apply for WH HPP 09 006 Funding Number: WH HPP 09 006 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $200,000 |
| 2009 Community Based Surveillance System to Monitor Peri Natal Outcomes within Districts Seven and Eight of Kabul, Afghanistan. Apply for GH GHS 09 002 Funding Number: GH GHS 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $400,000 |
| FY09 Hospital Leadership and Management Capacity Building for Rabia Balkhi Hospital, Kabul, Afghanistan. Apply for GH AWT 09 002 Funding Number: GH AWT 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,000,000 |
| FY09 Youth Empowerment Program (YEP) Apply for MP YEP 09 002 Funding Number: MP YEP 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $300,000 |
| FY09 Health Care Provider Response to Violence Against Women Education, Training and Technical Assistance Program Apply for WH AST 09 001 Funding Number: WH AST 09 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $1,500,000 |
| FY09 Announcement of Availability of Funds for the Emergency System for Advance Registration of Volunteer Health Professionals (ESAR VHP) Program. Apply for EP U3R 09 004 Funding Number: EP U3R 09 004 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $60,000 |
| Part C EIS CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE Apply for HRSA 10 008 Funding Number: HRSA 10 008 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| HIV Prevention Projects Apply for CDC RFA PS10 1001 Funding Number: CDC RFA PS10 1001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Human Immunodeficiency Virus (HIV) Prevention Projects for the Pacific Islands Apply for CDC RFA PS10 1002 Funding Number: CDC RFA PS10 1002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Comprehensive Faith Based HIV/AIDS Prevention, Care and Treatment Apply for RFA 617 09 000003 Funding Number: RFA 617 09 000003 Agency: Uganda USAID Kampala Category: Health Funding Amount: $30,000,000 |
| Initiative to Maximize Research Education in Genomics (R25) Apply for PAR 09 245 Funding Number: PAR 09 245 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Service Area Competitions Additional Areas Apply for HRSA 10 002 Funding Number: HRSA 10 002 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competitions Additional Areas Apply for HRSA 10 003 Funding Number: HRSA 10 003 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| FY09 Hispanic Physicians Leadership Development Initiative Apply for MP MPC 09 012 Funding Number: MP MPC 09 012 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| Immunobiology of Xenotransplantation (U01, U19) Apply for RFA AI 09 035 Funding Number: RFA AI 09 035 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Areas Apply for HRSA 10 158 Funding Number: HRSA 10 158 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 09 029", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.